The report was prompted by the FDA's 2021 approval of the Alzheimer's disease drug aducanumab (Aduhelm) using the accelerated approval pathway. The aducanumab approval raised concerns in Congress ...
In June 2021, the Food and Drug Administration approved aducanumab, an amyloid beta-targeted drug, under the “accelerated approval” program for patients diagnosed with Alzheimer’s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback